Effect of 4 Weeks Treatment With Acipimox in Patients With Chronic Heart Failure

Not Applicable

Completed

• Conditions: Heart Failure
• Interventions: Drug: placebo; Drug: acipimox

• Registration Number: NCT00549614
• Lead Sponsor: University of Aarhus

Brief Summary

The primary objective of this study is to evaluate whether metabolic modulation improves left ventricular function, work capacity, insulin sensitivity and modifies substrate metabolism in chronic heart failure

Detailed Description

Not available

Study Timeline

• Study Start: 2007-10
• Study First Submitted: 2007-10-25
• Study First Submitted QC: 2007-10-25
• Study First Posted: 2007-10-26
• Primary Completion: 2008-12
• Study Completion: 2009-05
• Status Verified: 2009-10
• Last Update Submitted: 2009-10-06
• Last Update Posted: 2009-10-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

• EF<40 %
• IHD
• NYHA-class II-III.

Exclusion Criteria

• pregnancy
• severe renal failure
• new brady- or tachyArrhythmia
• Severe stenotic valvular disease
• myocardial infarction within last 6 weeks
• insulin treated diabetes mellitus
• peptic ulcer
• pregnancy or lactating women
• allergy towards tested medicine

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
2	placebo	-
1	acipimox	-

Primary Outcome Measures

Name	Time	Method
left ventricular ejection Fraction	4 weeks
exercise capacity	4 weeks
muscular metabolism	4 weeks

Secondary Outcome Measures

Name	Time	Method
regional left ventricular function	4 weeks
insulin resistance	4 weeks
full body metabolism	4 weeks

Trial Locations

Locations (1)

Department of Cardiology, Aarhus Universityhospital, Skejby; 🇩🇰 Aarhus N, Denmark